Quote:
Originally Posted by reverett123
Neurodegener Dis. 2010 Feb 27. [Epub ahead of print]
Low Dosage of Rasagiline and Epigallocatechin Gallate Synergistically Restored the Nigrostriatal Axis in MPTP-Induced Parkinsonism.
Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA.
Eve Topf Center for Neurodegenerative Diseases Research and Department of Molecular Pharmacology, Faculty of Medicine, Technion, Haifa, Israel.
Abstract
Background: The anti-Parkinson monoamine oxidase B inhibitor rasagiline appears to be the first neuroprotective disease-modifying therapy in early-stage Parkinson's disease (PD). Objective: Using a polypharmacy paradigm, we tested whether the distinct neuroprotective pharmacological profile of rasagiline would complement that of (-)-epigallocatechin-3-gallate (EGCG), the main antioxidant/iron chelator polyphenol constituent of green tea, and restore the neuronal loss and molecular targets damaged in animal parkinsonism. Methods/Results: We show by high-performance liquid chromatography, immunohistochemistry and Western blot analyses that the combination of rasagiline and EGCG, at subliminal doses which have no profound protective effect, acts synergistically to restore the nigrostriatal axis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. A detailed analysis revealed a complementary action of these drugs, differentially acting at MPTP-injured molecules/targets in the substantia nigra (SN): induction of brain-derived neurotrophic factor by rasagiline, increased membranal levels of the protein kinase C alpha-isoform by EGCG and a synergistic replenishment of their downstream effector, the serine/threonine kinase Akt/protein kinase B, suggesting that this kinase might represent one point of convergence of the distinct mechanisms of action of the drug cocktail. Conclusion: These results provide molecular evidence that activation of multiple brain targets by the combination of rasagiline and EGCG may synergistically contribute to the rescue of the dopamine neurons in the SN and replenishment of striatal dopamine. This may have important implications for rasagiline-treated PD patients who could further benefit from an adjunct administration of EGCG.
PMID: 20197647 [PubMed - as supplied by publisher]
|
When I was diagnosed I found an article about neuroprotection by green tea. One of the authors is co-inventor of rasagiline (Moussa Youdim) so I considered the information relevant. I asked my neurologist and he said there's no problem in taking it, so I've been taking Azilect and green tea capsules for the last 10 months.
I know it's too early, but I haven't noticed any worsening in my condition, so I'll keep betting on this combination: rasagiline, EGCG and exercise.
For those interested the article is available
here. There's even an indication of the dosis: 2mg/Kg. Above that neuroprotection could turn into neurotoxicity.